1. Home
  2. AFYA vs AUPH Comparison

AFYA vs AUPH Comparison

Compare AFYA & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AFYA
  • AUPH
  • Stock Information
  • Founded
  • AFYA 1999
  • AUPH 1993
  • Country
  • AFYA Brazil
  • AUPH Canada
  • Employees
  • AFYA N/A
  • AUPH N/A
  • Industry
  • AFYA Other Consumer Services
  • AUPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • AFYA Real Estate
  • AUPH Health Care
  • Exchange
  • AFYA Nasdaq
  • AUPH Nasdaq
  • Market Cap
  • AFYA 1.4B
  • AUPH 1.6B
  • IPO Year
  • AFYA 2019
  • AUPH 1999
  • Fundamental
  • Price
  • AFYA $14.73
  • AUPH $15.39
  • Analyst Decision
  • AFYA Hold
  • AUPH Strong Buy
  • Analyst Count
  • AFYA 5
  • AUPH 3
  • Target Price
  • AFYA $18.10
  • AUPH $17.67
  • AVG Volume (30 Days)
  • AFYA 108.0K
  • AUPH 2.0M
  • Earning Date
  • AFYA 11-12-2025
  • AUPH 11-04-2025
  • Dividend Yield
  • AFYA 1.57%
  • AUPH N/A
  • EPS Growth
  • AFYA 25.39
  • AUPH N/A
  • EPS
  • AFYA 1.50
  • AUPH 0.55
  • Revenue
  • AFYA $681,742,784.00
  • AUPH $265,808,000.00
  • Revenue This Year
  • AFYA $14.70
  • AUPH $17.33
  • Revenue Next Year
  • AFYA $8.36
  • AUPH $14.31
  • P/E Ratio
  • AFYA $9.66
  • AUPH $28.16
  • Revenue Growth
  • AFYA 14.07
  • AUPH 20.62
  • 52 Week Low
  • AFYA $13.47
  • AUPH $6.55
  • 52 Week High
  • AFYA $19.90
  • AUPH $16.20
  • Technical
  • Relative Strength Index (RSI)
  • AFYA 52.37
  • AUPH 70.93
  • Support Level
  • AFYA $13.86
  • AUPH $14.93
  • Resistance Level
  • AFYA $15.27
  • AUPH $15.78
  • Average True Range (ATR)
  • AFYA 0.43
  • AUPH 0.83
  • MACD
  • AFYA 0.08
  • AUPH 0.15
  • Stochastic Oscillator
  • AFYA 64.65
  • AUPH 80.90

About AFYA Afya Limited

Afya Ltd is a medical education group based in Brazil. Its education portfolio has several courses in addition to Medicine, such as Management, Dentistry, Law, Engineering, Nursing, Psychology, and Accounting Sciences, among others. It has three segments; Undergrad provides educational services through undergraduate courses related to medical school, undergraduate health science and other ex-health undergraduate programs, Continuing Education provides medical education, specialization and graduate courses in medicine, delivered through digital and in-person content; and Medical practice solution provides clinical decision, clinical management and doctor-patient relationships for physicians and provide access, demand and efficiency for the healthcare players.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: